Amoeba

ALMIBFR0011051598

Filings

76 filings

All Inside information76 AGM documents3 Universal registration document3 Annual financial report2 Earnings release2 Half-year financial report2

23/07/2026
Amoéba and Koppert extend their distribution agreement for AXPERA technology and reaffirm their shared ambitions in the field of innovative biofungicides
Inside informationFR
30/06/2026
Amoéba has received marketing authorization in France for its biofungicide AXPERA
Inside informationFR
08/06/2026
Amoéba obtains in Italy a 120 day emergency authorization for the use of its biofungicide AXPERA against basil downy mildew
Inside informationFR
06/05/2026
Two new exceptional trial permits in the Netherlands in 2026 for Amoéba's biocontrol solution
Inside informationFR
28/04/2026
Amoéba has obtained a new emergency authorization for the use of the AXPERA biocontrol solution to protect French vineyards
Inside informationFR
13/04/2026
Amoéba and Koppert highlight the potential of AXPERA technology in Brazil for strategic crops
Inside informationFR
26/03/2026
Amoéba announces the success of its capital increase and raises EUR 6.67 million
Inside informationFR
25/03/2026
Amoéba strengthens its financial visibility to support its industrial and commercial expansion
Inside informationFR
11/03/2026
Amoéba receives its first order from Koppert and confirms its transformation into a commercial company
Inside informationFR
23/02/2026
Amoéba: final phase for marketing authorisation of AXPERA
Inside informationFR
18/12/2025
AXPERA wins the SIVAL d'Or Award: further recognising of the effectiveness of Amoéba's biocontrol solution
Inside informationFR
20/11/2025
Amoéba organise une visioconférence ouverte à tous le lundi 1er décembre 2025 à 18h
Inside informationFrench
18/11/2025
A natural breakthrough in protecting cereals and field crops // Syngenta and Amoeba SA to develop and commercialize biocontrol solutions for EU and UK
Inside informationFR
29/10/2025
Amoéba presents the 2025 results of its vineyard trial campaign: AXPERA confirms its effectiveness against downy mildew and its strong potential to significantly reduce copper use
Inside informationFR
20/10/2025
AXPERA named biocontrol solution of the year 2025 // Amoeba's anti-fungal innovation wins the Gold Award at the 2025 Bernard Blum Awards
Inside informationFR
16/10/2025
Amoéba obtains market authorisation in the United States for its AXPERA biocontrol solution
Inside informationFR
15/10/2025
Amoéba announces the appointment of Jean-Marc PETAT as Managing Director of Green 4 Agro, its dedicated subsidiary for biocontrol and biostimulants in agriculture
Inside informationFR
09/10/2025
Amoéba: a first half of 2025 marked by numerous decisive achievements ahead of the commercial launch of its biocontrol solution in 2026
Inside informationFR
02/10/2025
Amoéba accelerates the development of Axpera: Very convincing results observed by winegrowers; An approval schedule in line with the market launch in 2026.
Inside informationFR
08/09/2025
Amoéba: Edison sets a target price of EUR 2.01
Inside informationFR
23/07/2025
Amoéba announces the success of its capital increase of 14 M EUR to support its industrial and commercial deployment
Inside informationFR
22/07/2025
Amoéba launches a capital increase open to all to support its industrial and commercial deployment
Inside information
22/07/2025
Amoéba signs an agreement with Metron Technology, a subsidiary of Oriental Beauty Valley (OBV), a key player in the cosmetics industry in China
Inside informationFR
22/07/2025
Amoéba lance une augmentation de capital ouverte à tous pour soutenir son déploiement industriel et commercial
Inside informationFrench
25/06/2025
Exemption from the obligation to destroy crops in France obtained by Amoéba
Inside informationFR
17/06/2025
Amoéba takes another decisive step forward with the final approval of its biocontrol active substance by the European Commission
Inside informationFR
03/06/2025
Koppert and Amoéba sign major distribution agreement for innovative biofungicide solution
Inside informationFR
21/05/2025
A new milestone towards the market launch of AXPERA: EU Member States unanimously vote in favour of the approval of Amoéba's biocontrol active substance
Inside informationFR
20/05/2025
Amoéba announces the nomination of Charlotte Franceries, a leading figure in the cosmetics and communications industry, to its Board of Directors
Inside informationFR
12/05/2025
Amoéba and Koppert continue to prepare the commercial launch of AXPERA, the biocontrol product developed by Amoéba.
Inside informationFR
06/05/2025
Amoéba obtains an exceptional exemption in the Netherlands for its biocontrol product AXPERA for large-scale greenhouse trials
Inside informationFR
22/04/2025
New strategic milestone for Amoéba: Axpéra biocontrol product receives emergency market authorisation in France // A proven new solution to help winegrowers combat grapevine downy mildew
Inside informationFR
14/04/2025
Amoéba announces a second initiation of coverage by KBC Securities and confirms its new international dimension
Inside informationFR
01/04/2025
Amoéba signs a Memorandum of Understanding with Metron Technology, a subsidiary of the Oriental Beauty Valley (OBV) group, the undisputed leader in cosmetics in China
Inside informationFR
27/03/2025
Following decisive advances and a significant improvement in its results in 2024, Amoéba is approaching 2025 with confidence and is getting closer to commercialising its first products
Inside informationFR
20/03/2025
Amoéba is the French partner in the European SAGROPIA project
Inside informationFR
13/03/2025
Amoéba participe à la 3ème édition du Retail Day organisée par Euroland Corporate et Bourse Direct le jeudi 20 mars 2025
Inside informationFrench
10/03/2025
Amoéba confirms the extension of production capacity of its Chassieu site (France) to support its commercial deployment
Inside informationFR
23/01/2025
Amoéba announces the initiation of coverage of its stock by Euroland Corporate with a target price of EUR 2.40
Inside informationFR
15/01/2025
Amoéba announces the publication of the EFSA's final report confirming its positive and definitive conclusions
Inside informationFR

About

ISIN: FR0011051598
Ticker: ALMIB
LEI: 9695005QNE7C8Z0LXU64
Country of registration: FR
Last filing: 23/07/2026, 18:00

Sparse profile

The AMF publishes neither sector nor description. These fields are enriched from Wikidata where a match exists.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive